Published in Vaccine Weekly, November 21st, 2007
"The initiation of this dose-finding study is an important milestone in our development of valomaciclovir," said Fred Volinsky, MD, Chief Executive Officer. "Shingles, especially in the elderly population, can pose a serious threat to quality of life. Despite the approval of the adult zoster vaccine, we believe that the potential market for effective zoster medications will double in size based on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly